DOCSLIB.ORG

Genetically Modified and Cloned Animals. All in a Good Cause? a Report by Genewatch UK Genetically Modified and Cloned Animals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetically Modified and Cloned Animals. All in a Good Cause? a Report by Genewatch UK Genetically Modified and Cloned Animals Genetically Modified and Cloned Animals. All in a Good Cause? A Report by GeneWatch UK Genetically Modified and Cloned Animals. All in a Good Cause? By Jay Rutovitz and Sue Mayer April 2002 The Mill House, Manchester Road, Tideswell, Buxton, Derbyshire, SK17 8LN GeneWatch Phone: 01298 871898 Fax: 01298 872531 UK E-mail: [email protected] Website: www.genewatch.org The research and production of the report was supported by a grant from The Body Shop Foundation. Acknowledgments We are grateful to Vicky Robinson and Julia Wrathall of the RSPCA, Gill Langley of the Dr Hadwen Trust, Jacky Turner of Compassion in World Farming and Stephen Blakeway of Vetwork UK for their helpful comments on a draft of this report. The content of the final report remains the responsibility of the authors alone. Cover photograph: Gaur Standing, © Advanced Cell Technology, Inc., Worcester, Massachusetts. The gaur calf, ‘Noah’, born in January 2001, was cloned from an adult gaur with a cow as a surrogate mother. The calf died 48 hours after birth from an infection. The gaur is an endangered species and the calf was cloned as part of an attempt to preserve the species. CONTENTS EXECUTIVE SUMMARY......................................................................................................... 6 1 INTRODUCTION ............................................................................................................. 10 1.1 Scope of the report .................................................................................................... 11 1.2 GeneWatch UK’s position .......................................................................................... 11 2 OVERVIEW OF THE TECHNOLOGY ............................................................................ 12 2.1 What modifications have taken place?...................................................................... 12 2.2 Genetic modification techniques................................................................................ 12 2.2.1 How does it work? .............................................................................................. 12 2.2.2 Microinjection ...................................................................................................... 14 2.2.3 Viral transfection ................................................................................................. 15 2.2.4 Embryonic stem cell modification ....................................................................... 16 2.2.5 Sperm mediated transfer .................................................................................... 16 2.2.6 Poultry ................................................................................................................. 16 2.2.7 Cloning ................................................................................................................ 17 2.2.8 Localised gene transfer ...................................................................................... 17 2.3 What does genetic modification involve for the animal? ........................................... 18 2.4 How successful is genetic modification? ................................................................... 18 2.5 What stage is the technology at? .............................................................................. 19 3 ETHICS ........................................................................................................................... 21 3.1 Species integrity and crossing species barriers ........................................................ 21 3.2 Utilitarianism ...............................................................................................................22 3.3 The human-animal relationship ................................................................................. 23 3.4 Conclusion ................................................................................................................. 23 4 ANIMAL WELFARE......................................................................................................... 24 4.1 Reproductive and other medical interventions .......................................................... 24 4.2 Mutations....................................................................................................................25 4.3 Expression of the transgene and unexpected effects ............................................... 25 4.4 Wastage ..................................................................................................................... 26 4.5 Housing and husbandry effects ................................................................................. 26 4.6 Conclusion ................................................................................................................. 26 5 LABORATORY ANIMALS ............................................................................................... 28 5.1 Species integrity and our relationship to laboratory mice.......................................... 29 5.2 Basic biological research ........................................................................................... 30 5.3 Disease models ......................................................................................................... 31 5.4 Safety testing ............................................................................................................. 33 5.5 Alternatives ................................................................................................................ 35 5.6 Welfare....................................................................................................................... 37 5.7 Conclusion ................................................................................................................. 37 6 PHARMACEUTICAL PRODUCTION – ‘PHARMING’ ..................................................... 39 6.1 Commercialisation...................................................................................................... 39 6.2 Alternatives ................................................................................................................ 45 6.3 Effect on animals’ welfare .......................................................................................... 46 6.4 Safety ......................................................................................................................... 47 6.5 Conclusion ................................................................................................................. 48 7 AGRICULTURE ............................................................................................................... 49 7.1 Meat production ......................................................................................................... 50 7.2 Wool production ......................................................................................................... 55 7.3 Milk production ........................................................................................................... 55 GeneWatch UK April 2002 4 7.4 Disease resistance ..................................................................................................... 56 7.5 Phosphate reduction - the ‘enviro-pig’ ....................................................................... 57 7.6 BioSteel® production ................................................................................................. 58 7.7 Conclusion ................................................................................................................. 58 8 XENOTRANSPLANTATION............................................................................................ 60 8.1 The organ ‘gap’ .......................................................................................................... 60 8.2 History and the application of genetic technologies .................................................. 60 8.3 Success rates ............................................................................................................ 61 8.4 Risks of xenotransplantation ..................................................................................... 62 8.4.1 Transfer of disease-causing organisms ............................................................. 62 8.4.2 Incompatible physiology ..................................................................................... 63 8.5 Threats to animal welfare .......................................................................................... 63 8.6 Who’s involved? ......................................................................................................... 64 8.7 Alternatives ................................................................................................................ 65 8.8 Conclusion ................................................................................................................. 66 9 CLONING ........................................................................................................................67 9.1 Abnormalities ............................................................................................................. 67 9.2 Companion animals ................................................................................................... 69 9.3 Cloning extinct and endangered species .................................................................. 69 9.4 Conclusion ................................................................................................................
Load more

Recommended publications
  • Welfare Issues with Genetic Engineering and Cloning of Farm Animals
    WellBeing International WBI Studies Repository 2006 Welfare Issues with Genetic Engineering and Cloning of Farm Animals The Humane Society of the United States Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/ hsus_reps_impacts_on_animals Part of the Animal Studies Commons, Bioethics and Medical Ethics Commons, and the Other Genetics and Genomics Commons Recommended Citation The Humane Society of the United States, "Welfare Issues with Genetic Engineering and Cloning of Farm Animals" (2006). IMPACTS ON FARM ANIMALS. 21. https://www.wellbeingintlstudiesrepository.org/hsus_reps_impacts_on_animals/21 This material is brought to you for free and open access by WellBeing International. It has been accepted for inclusion by an authorized administrator of the WBI Studies Repository. For more information, please contact [email protected]. Farm Animal Welfare • The HSUS 2100 L St., N.W. • Washington, DC 20037 • HSUS.org 202-452-1100 • F: 301-258-3081 • FarmAnimalWelfare.org An HSUS Report: Welfare Issues with Genetic Engineering and Cloning of Farm Animals Abstract Developments in biotechnology have raised new concerns about animal welfare, as farm animals now have their genomes modified (genetically engineered) or copied (cloned) to propagate certain traits useful to agribusiness, such as meat yield or feed conversion. These animals suffer from unusually high rates of birth defects, disabili- ties, and premature death. Genetically engineering farm animals for greater bone strength or reduced pain reception, for example, may result in improved well-being, yet the broad use of this technology often causes increased suffering. The limited success of gene insertion techniques can result in genes failing to reach target cells and finishing in cells of unintended organs, and abnormally developed embryos may die in utero, be infertile, or born with development defects, attributable in part to insertional problems.
    [Show full text]
  • Gene Use Restriction Technologies for Transgenic Plant Bioconfinement
    Plant Biotechnology Journal (2013) 11, pp. 649–658 doi: 10.1111/pbi.12084 Review article Gene use restriction technologies for transgenic plant bioconfinement Yi Sang, Reginald J. Millwood and C. Neal Stewart Jr* Department of Plant Sciences, University of Tennessee, Knoxville, TN, USA Received 1 February 2013; Summary revised 3 April 2013; The advances of modern plant technologies, especially genetically modified crops, are considered accepted 9 April 2013. to be a substantial benefit to agriculture and society. However, so-called transgene escape *Correspondence (fax 1-865-974-6487; remains and is of environmental and regulatory concern. Genetic use restriction technologies email [email protected]) (GURTs) provide a possible solution to prevent transgene dispersal. Although GURTs were originally developed as a way for intellectual property protection (IPP), we believe their maximum benefit could be in the prevention of gene flow, that is, bioconfinement. This review describes the underlying signal transduction and components necessary to implement any GURT system. Keywords: transgenic plants, Furthermore, we review the similarities and differences between IPP- and bioconfinement- transgene escape, male sterility, oriented GURTs, discuss the GURTs’ design for impeding transgene escape and summarize embryo sterility, transgene deletion, recent advances. Lastly, we go beyond the state of the science to speculate on regulatory and gene flow. ecological effects of implementing GURTs for bioconfinement. Introduction proposed (Daniell, 2002; Gressel, 1999; Moon et al., 2011), including strategies for male sterility (Mariani et al., 1990), Transgenic crops have become an integral part of modern maternal inheritance (Daniell et al., 1998; Iamtham and Day, agriculture and have been increasingly adopted worldwide (James, 2000; Ruf et al., 2001), transgenic mitigation (Al-Ahmad et al., 2011).
    [Show full text]
  • Cloning: Adult Vs. Embryonic Cells and Techniques Employed
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Supervised Undergraduate Student Research Chancellor’s Honors Program Projects and Creative Work Spring 5-2001 Cloning: Adult vs. Embryonic Cells and Techniques Employed Rebecca Ruth Frazor University of Tennessee-Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_chanhonoproj Recommended Citation Frazor, Rebecca Ruth, "Cloning: Adult vs. Embryonic Cells and Techniques Employed" (2001). Chancellor’s Honors Program Projects. https://trace.tennessee.edu/utk_chanhonoproj/459 This is brought to you for free and open access by the Supervised Undergraduate Student Research and Creative Work at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Chancellor’s Honors Program Projects by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. UNIVERSITY HONORS PROGRAM SENIOR PROJECT - APPROVAL Name: Getec eCA f?- f(CAZOr College: AQn eMi:hA rv Department: A1 (met I SCi!A1w -J Faculty Mentor: F. N-S ChV\C ¥: PROJECT TITLE: C10l/1\(}q : Adult \[) ' fmmrVVl l0 C l, (( ~ ~rd the. ~ Qr\L\A<; Icchn \ quc ~ Emplo\( f d I have reviewed this completed senior honors thesis with this student and certify that it is a project commens rate with rs level undergraduate research in this field. Signed: ;. ./-1 Faculty Mentor Date: _-+-'""-+----L-___ Comments (Optional): Cloning: Adult vs. Embryonic Cells and Various Techniques Employed Rebecca R. Frazor Mentor: F. Neal Schrick Senior Honors Project May 2001 Abstract The cloning of amphibians and mainly mammals is discussed focusing on somatic cell usage. Significant progress has been made in recent years and this is outlined with an emphasis on techniques and their differences.
    [Show full text]
  • Direct Cloning and Refactoring of a Silent Lipopeptide Biosynthetic Gene Cluster Yields the Antibiotic Taromycin A
    Direct cloning and refactoring of a silent lipopeptide biosynthetic gene cluster yields the antibiotic taromycin A Kazuya Yamanakaa,b, Kirk A. Reynoldsa,c, Roland D. Kerstena, Katherine S. Ryana,d, David J. Gonzaleze, Victor Nizete,f, Pieter C. Dorresteina,c,f, and Bradley S. Moorea,f,1 aScripps Institution of Oceanography, University of California, San Diego, La Jolla, CA 92093; bYokohama Research Center, JNC Corporation, Yokohama 236-8605, Japan; cDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093; dDepartment of Chemistry, University of British Columbia, Vancouver, BC, Canada V62 1Z4; and Departments of ePediatrics and fSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093 Edited by Jerrold Meinwald, Cornell University, Ithaca, NY, and approved December 23, 2013 (received for review October 23, 2013) Recent developments in next-generation sequencing technologies genes (9, 10). Synthetic biology approaches also can be used to have brought recognition of microbial genomes as a rich resource refactor orphan gene clusters by optimizing promoters, tran- for novel natural product discovery. However, owing to the scar- scriptional regulation, ribosome-binding sites, and even codon city of efficient procedures to connect genes to molecules, only use (11). Examples of successful regulatory gene manipulation to a small fraction of secondary metabolomes have been investigated elicit the production of new natural products from silent bio- to date. Transformation-associated recombination (TAR) cloning synthetic gene clusters in WT strains have been reported in takes advantage of the natural in vivo homologous recombination bacteria and fungi (12, 13); however, this approach requires the of Saccharomyces cerevisiae to directly capture large genomic loci.
    [Show full text]
  • Dolly the Sheep – the First Cloned Adult Animal
    DOLLY THE SHEEP – THE FIRST CLONED ADULT ANIMAL NEW TECHNOLOGY FOR IMPROVING LIVESTOCK From Squidonius via Wikimedia Commons In 1996, University of Edinburgh scientists celebrated the birth of Dolly the Sheep, the first mammal to be cloned using SCNT cloning is the only technology adult somatic cells. The Edinburgh team’s success followed available that enables generation of 99.8% its improvements to the single cell nuclear transfer (SCNT) genetically identical offspring from selected technique used in the cloning process. individuals of adult animals (including sterilized animals). As such, it is being Dolly became a scientific icon recognised worldwide and exploited as an efficient multiplication tool SCNT technology has spread around the world and has been to support specific breeding strategies of used to clone multiple farm animals. farm animals with exceptionally high genetic The cloning of livestock enables growing large quantities of value. the most productive, disease resistant animals, thus providing more food and other animal products. Sir Ian Wilmut (Inaugural Director of MRC Centre for Regeneration and Professor at CMVM, UoE) and colleagues worked on methods to create genetically improved livestock by manipulation of stem cells using nuclear transfer. Their research optimised interactions between the donor nucleus and the recipient cytoplasm at the time of fusion and during the first cell cycle. Nuclear donor cells were held in mitosis before being released and used as they were expected to be passing through G1 phase. CLONING IN COMMERCE, CONSERVATION OF AGRICULTURE AND PRESERVATION ANIMAL BREEDS OF LIVESTOCK DIVERSITY Cloning has been used to conserve several animal breeds in the recent past.
    [Show full text]
  • The Use of Non-Human Primates in Research in Primates Non-Human of Use The
    The use of non-human primates in research The use of non-human primates in research A working group report chaired by Sir David Weatherall FRS FMedSci Report sponsored by: Academy of Medical Sciences Medical Research Council The Royal Society Wellcome Trust 10 Carlton House Terrace 20 Park Crescent 6-9 Carlton House Terrace 215 Euston Road London, SW1Y 5AH London, W1B 1AL London, SW1Y 5AG London, NW1 2BE December 2006 December Tel: +44(0)20 7969 5288 Tel: +44(0)20 7636 5422 Tel: +44(0)20 7451 2590 Tel: +44(0)20 7611 8888 Fax: +44(0)20 7969 5298 Fax: +44(0)20 7436 6179 Fax: +44(0)20 7451 2692 Fax: +44(0)20 7611 8545 Email: E-mail: E-mail: E-mail: [email protected] [email protected] [email protected] [email protected] Web: www.acmedsci.ac.uk Web: www.mrc.ac.uk Web: www.royalsoc.ac.uk Web: www.wellcome.ac.uk December 2006 The use of non-human primates in research A working group report chaired by Sir David Weatheall FRS FMedSci December 2006 Sponsors’ statement The use of non-human primates continues to be one the most contentious areas of biological and medical research. The publication of this independent report into the scientific basis for the past, current and future role of non-human primates in research is both a necessary and timely contribution to the debate. We emphasise that members of the working group have worked independently of the four sponsoring organisations. Our organisations did not provide input into the report’s content, conclusions or recommendations.
    [Show full text]
  • DRAFT Landscape of COVID-19 Candidate Vaccines – 10 August 2020
    DRAFT landscape of COVID-19 candidate vaccines – 10 August 2020 28 candidate vaccines in clinical evaluation COVID-19 Vaccine Number of Route of Clinical Stage Vaccine platform Type of candidate vaccine Timing of doses developer/manufacturer doses Administration Phase 1 Phase 1/2 Phase 2 Phase 3 PACTR202006922165132 Non-Replicating University of Oxford/AstraZeneca ChAdOx1-S 1 IM 2020-001072-15 2020-001228-32 ISRCTN89951424 Viral Vector Interim Report NCT04383574 Sinovac Inactivated Inactivated 2 0, 14 days IM NCT04456595 NCT04352608 Wuhan Institute of Biological Inactivated Inactivated 2 0,14 or 0,21 days IM ChiCTR2000031809 ChiCTR2000034780 Products/Sinopharm Beijing Institute of Biological Inactivated Inactivated 2 0,14 or 0,21 days IM ChiCTR2000032459 ChiCTR2000034780 Products/Sinopharm NCT04283461 NCT04405076 NCT04470427 Moderna/NIAID RNA LNP-encapsulated mRNA 2 0, 28 days IM Interim Report 2020-001038-36 BioNTech/Fosun Pharma/Pfizer RNA 3 LNP-mRNAs 2 0, 28 days IM NCT04368728 ChiCTR2000034825 CanSino Biological Inc./Beijing Institute Non-Replicating ChiCTR2000030906 ChiCTR2000031781 Adenovirus Type 5 Vector 1 IM of Biotechnology Viral Vector Study Report Study Report Anhui Zhifei Longcom Adjuvanted recombinant protein 0,28 or 0,28,56 Protein Subunit 2 or 3 IM NCT04445194 NCT04466085 Biopharmaceutical/Institute of (RBD-Dimer) days DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities).
    [Show full text]
  • Association for Consumer Research
    ASSOCIATION FOR CONSUMER RESEARCH Labovitz School of Business & Economics, University of Minnesota Duluth, 11 E. Superior Street, Suite 210, Duluth, MN 55802 Cyborg As Commodity: Exploring Conceptions of Self-Identity, Body and Citizenship Within the Context of Emerging Transplant Technologies Ai-Ling Lai, University of Leicester, UK This paper explores how advances in transplant technologies shape conceptions of self-identity, embodiment and citizenship. Drawing on the posthuman writing of Donna Haraway and through phenomenological interviews, I explore ambivalence towards the commoditization of the cyborg-body, suggesting that biotechnology may potentially lead to a dystopian posthuman consumer society. [to cite]: Ai-Ling Lai (2012) ,"Cyborg As Commodity: Exploring Conceptions of Self-Identity, Body and Citizenship Within the Context of Emerging Transplant Technologies ", in NA - Advances in Consumer Research Volume 40, eds. Zeynep Gürhan-Canli, Cele Otnes, and Rui (Juliet) Zhu, Duluth, MN : Association for Consumer Research, Pages: 386-394. [url]: http://www.acrwebsite.org/volumes/1011658/volumes/v40/NA-40 [copyright notice]: This work is copyrighted by The Association for Consumer Research. For permission to copy or use this work in whole or in part, please contact the Copyright Clearance Center at http://www.copyright.com/. Cyborg as Commodity: Exploring Conception of Self-Identity, Body and Citizenship within the Context of Emerging Transplant Technologies Ai-Ling Lai, University of Leicester, UK ABSTRACT technology (Thompson 2004). In doing so, I aim to contribute to This paper explores how advances in transplant technologies previous writings by Johnson and Roberts (1997) and Belk (1990). shape conceptions of self-identity, embodiment and citizenship. Most notably, these scholars observe how the marketing of organ Drawing on the posthuman writing of Donna Haraway and from transplantation has previously been predicated on the ‘mechanistic’ phenomenological interviews, I explore ambivalence towards the metaphor of the body (Belk 1990).
    [Show full text]
  • The Bio Revolution: Innovations Transforming and Our Societies, Economies, Lives
    The Bio Revolution: Innovations transforming economies, societies, and our lives economies, societies, our and transforming Innovations Revolution: Bio The Executive summary The Bio Revolution Innovations transforming economies, societies, and our lives May 2020 McKinsey Global Institute Since its founding in 1990, the McKinsey Global Institute (MGI) has sought to develop a deeper understanding of the evolving global economy. As the business and economics research arm of McKinsey & Company, MGI aims to help leaders in the commercial, public, and social sectors understand trends and forces shaping the global economy. MGI research combines the disciplines of economics and management, employing the analytical tools of economics with the insights of business leaders. Our “micro-to-macro” methodology examines microeconomic industry trends to better understand the broad macroeconomic forces affecting business strategy and public policy. MGI’s in-depth reports have covered more than 20 countries and 30 industries. Current research focuses on six themes: productivity and growth, natural resources, labor markets, the evolution of global financial markets, the economic impact of technology and innovation, and urbanization. Recent reports have assessed the digital economy, the impact of AI and automation on employment, physical climate risk, income inequal ity, the productivity puzzle, the economic benefits of tackling gender inequality, a new era of global competition, Chinese innovation, and digital and financial globalization. MGI is led by three McKinsey & Company senior partners: co-chairs James Manyika and Sven Smit, and director Jonathan Woetzel. Michael Chui, Susan Lund, Anu Madgavkar, Jan Mischke, Sree Ramaswamy, Jaana Remes, Jeongmin Seong, and Tilman Tacke are MGI partners, and Mekala Krishnan is an MGI senior fellow.
    [Show full text]
  • Genome As a Tool of Genetic Engineering: Application in Plant and Plant Derived Medicine
    International Journal of Biotech Trends and Technology (IJBTT) – Volume 8 Issue 1- Jan - March 2018 Genome as a Tool of Genetic Engineering: Application in Plant and Plant Derived Medicine A.B.M. Sharif Hossain1,2 Musamma M. Uddin2 1Department of Biology, Faculty of Science, Hail University, Hail, KSA 2Biotechnology Program, Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603, Kuala Lumpur, Malaysia introduce point mutations. Genetically modified Abstract organism (GMO) is considered as an organism that The study was conducted from different is generated through genetic engineering. The first modern research data to review the innovative GMOs were bacteria in 1973, GM mice were generated in 1974 [4]. Insulin-producing bacteria latest technology in the genomics and its were commercialized in 1982 and genetically application in Agriculture, biomedicinae and modified food has been sold since 1994. Glofish, the plant derived medicine. Application of genome first GMO designed as a pet, was first sold in the in genetic engineering and molecular United States December in 2003 [4]. Genetic biotechnology have been exhibited well. engineering biotechnology has been applied in Genetically Modified Organism (GMO), numerous fields including agriculture, industrial Agrobacterium mediated recombination (T- biotechnology, and medicine. Enzymes used in DNA) and genetic engineering using molecular laundry detergent and medicines such as insulin and Biotechnology in plant, medicine and human growth hormone are now manufactured in biomedicine have been highlighted from GM cells, experimental GM cell lines and GM animals such as mice or zebra fish are being used for technology based different research data. research purposes, and genetically modified Moreover, molecular biotechnology in crops have been commercialized [4].
    [Show full text]
  • Non-Human Primates in Biomedical Research
    Science Shop for Biology Non-human primates in biomedical research Frouke Pieters P-UB-2006-06 Non-human primates in biomedical research Reasons and alternatives for their use Frouke Pieters Science shop for Biology Netherlands Centre Alternatives to Animal Use, Utrecht University, The Netherlands April 2007 P-UB-2006-06 Colofon Report number P-UB-2006-06 ISBN 978-90-5209-158-7 Price € 5,- Publication date April 2007 Edition First Title Non-human primates in biomedical research Reasons and alternatives for their use Author Frouke Pieters Supervisor Prof. Dr. C. Hendriksen, Netherlands Centre Alternatives to animal use, Utrecht University, The Netherlands Project coordinator Ir. M. A. Vaal, Science Shop for Biology, Utrecht University Commissioned by Working party 'Primate Research in the Netherlands' under the auspices of the Dutch Association for Laboratory Animal Science, Amsterdam Reproduction Document Diensten Centrum Uithof Publisher Science shop for Biology, Utrecht University Padualaan 8, 3584 CH Utrecht, The Netherlands. .. 31 30 253 7363 www.bio.uu.nl/scienceshop Copyright This document (or parts thereof) may not be multiplied in any form. Parts of the document may be used for other publications, if a reference is included. Contents Preface 5 Summary 7 Samenvatting 8 1 Introduction 9 1.1 Motivation 9 1.2 Definition of the problem 10 1.3 Scope and definitions 10 1.4 Approach 11 1.5 Structure 12 2 Use of primates 13 2.1 Figures 13 2.2 Goals of primate studies 18 2.3 Regulations on animal experimentation 21 2.4 Ethics 22 2.5 Problems
    [Show full text]
  • Review of the Current State of Genetic Testing - a Living Resource
    Review of the Current State of Genetic Testing - A Living Resource Prepared by Liza Gershony, DVM, PhD and Anita Oberbauer, PhD of the University of California, Davis Editorial input by Leigh Anne Clark, PhD of Clemson University July, 2020 Contents Introduction .................................................................................................................................................. 1 I. The Basics ......................................................................................................................................... 2 II. Modes of Inheritance ....................................................................................................................... 7 a. Mendelian Inheritance and Punnett Squares ................................................................................. 7 b. Non-Mendelian Inheritance ........................................................................................................... 10 III. Genetic Selection and Populations ................................................................................................ 13 IV. Dog Breeds as Populations ............................................................................................................. 15 V. Canine Genetic Tests ...................................................................................................................... 16 a. Direct and Indirect Tests ................................................................................................................ 17 b. Single
    [Show full text]